Varied Sleep Patterns for Cardiometabolic Health
Trial Summary
What is the purpose of this trial?
The goal of this clinical trial is to test the impact of repeated intermittent short sleep, with short sleep maintained 5 days per week followed by 2 days of prolonged sleep, compared to daily adequate sleep, on energy balance and cardiometabolic risk. A secondary goal of this research is to determine if maintaining a constant midpoint of sleep while undergoing intermittent short sleep, leads to better outcomes than intermittent short sleep with a 2-hour delay in sleep midpoint. The aims of this research will be tested in the context of a 3-group, parallel-arm, outpatient intervention of 4 weeks in duration, in young-to-middle-aged adults (aged 18-49 years).
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot participate if you are taking beta-blockers, anti-coagulants, or anti-platelets.
What data supports the effectiveness of the treatment Varied Sleep Patterns for Cardiometabolic Health?
Is varied sleep pattern treatment safe for humans?
Research on varied sleep patterns, like social jetlag, suggests it may be linked to higher body weight and cardiometabolic risks, such as obesity and poor nutrient intake. However, these studies focus on associations rather than direct safety evaluations, so more research is needed to fully understand the safety of these sleep patterns.16789
How does the treatment of Intermittent Short Sleep (ISS) and Social Jetlag (SJL) differ from other treatments for cardiometabolic health?
This treatment is unique because it focuses on managing sleep patterns, specifically the timing and duration of sleep, to address cardiometabolic health. Unlike traditional treatments that might focus on medication or diet, this approach targets the circadian rhythm (the body's internal clock) and its impact on metabolism, which is a novel way to address issues like obesity and diabetes.1261011
Research Team
Marie-Pierre St-Onge, PhD
Principal Investigator
Columbia University
Eligibility Criteria
This trial is for adults aged 18-49 with a BMI of 20-29.9 who usually sleep 7-9 hours without aids or naps. It's not for those who've recently changed weight, are in weight loss programs, have had bariatric surgery, smoke, have sleep disorders, take certain blood medications, have psychiatric conditions including eating disorders and seasonal affective disorder, are pregnant or breastfeeding, have high blood pressure on beta-blockers or diabetes.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Intervention
Participants undergo a 3-group, parallel-arm, outpatient intervention to test the impact of sleep patterns on cardiometabolic health
Follow-up
Participants are monitored for safety and effectiveness after the intervention
Treatment Details
Interventions
- Intermittent Short Sleep (ISS) (Behavioral Intervention)
- Social Jetlag (SJL) (Behavioral Intervention)
- Sustained Adequate Sleep (SAS) (Behavioral Intervention)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Columbia University
Lead Sponsor
Dr. Katrina Armstrong
Columbia University
Chief Executive Officer
MD from Johns Hopkins University, MS in Epidemiology from Harvard School of Public Health
Dr. Katrina Armstrong
Columbia University
Chief Medical Officer
MD from Harvard Medical School
Icahn School of Medicine at Mount Sinai
Collaborator
Dr. Brendan Carr
Icahn School of Medicine at Mount Sinai
Chief Executive Officer since 2024
MD, MA, MS
Dr. Vicki LoPachin
Icahn School of Medicine at Mount Sinai
Chief Medical Officer
MD, FACP, MBA
University of Colorado, Denver
Collaborator
Aviva Abosch
University of Colorado, Denver
Chief Medical Officer since 2019
MD
Uday B. Kompella
University of Colorado, Denver
Chief Executive Officer since 2015
PhD in Pharmaceutical Sciences
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator
Dr. Gary H. Gibbons
National Heart, Lung, and Blood Institute (NHLBI)
Chief Executive Officer since 2012
MD from Harvard Medical School
Dr. James P. Kiley
National Heart, Lung, and Blood Institute (NHLBI)
Chief Medical Officer since 2011
MD from University of California, San Francisco